King Pharmaceuticals@, Inc. discontinues the manufacture of Tilade@ Inhaler (nedocromil sod ium inhalation aerosol).

King Pharmaceuticals@, Inc. has decided to discontinue the manufacture of Tilade@ Inhaler (nedocromil sod ium inhalation aerosol). TILADE@ will remain available through pharmacies and wholesalers until current supplies are depleted. TILADE® is distributed through King Pharmaceuticals@, Inc. No additional product will be available after King, pharmacy, and wholesaler supplies are exhausted. If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.
T1LADE® Inhaler is indicated for maintenance therapy in the management of adult and pediatric patients 6 years and older with mild to moderate asthma. Important Safety Information: TILADE Inhaler is contraindicated in patients who have shown hypersensitivity to nedocromil sodium or other ingredients in this preparation. TILADE® Inhaler (nedocromil sodium inhalation aerosol) is not a bronchodilator and, therefore, should not be used for the reversal of acute bronchospasm, particularly status asthmaticus. The role of TILADE as a corticosteroid-sparing agent in patients receiving oral or inhaled corticosteroids remains to be defined. If systemic or inhaled corticosteroid therapy is reduced in patients receiving T1LADE , careful monitoring is necessary. Common adverse reactions include unpleasant taste, coughing, pharyngitis, rhinitis, upper respiratory in fection, bronchospasm, and headache.

Tags: Drug Shortage, King Pharmaceuticals, Tilade Inhaler